rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2002-7-9
|
pubmed:abstractText |
Basiliximab is a chimeric human/mouse monoclonal antibody directed against the alpha chain of the IL-2 receptor, CD25, which has been reported as successfully reducing rejection in adult renal transplant recipients. Reported clinical experience of basiliximab in paediatric renal transplantation is limited.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0931-0509
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1304-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12105256-Antibodies, Monoclonal,
pubmed-meshheading:12105256-Antilymphocyte Serum,
pubmed-meshheading:12105256-Azathioprine,
pubmed-meshheading:12105256-Child,
pubmed-meshheading:12105256-Cyclosporine,
pubmed-meshheading:12105256-Drug Therapy, Combination,
pubmed-meshheading:12105256-Female,
pubmed-meshheading:12105256-Follow-Up Studies,
pubmed-meshheading:12105256-Graft Rejection,
pubmed-meshheading:12105256-Graft Survival,
pubmed-meshheading:12105256-Humans,
pubmed-meshheading:12105256-Immunosuppressive Agents,
pubmed-meshheading:12105256-Kidney Transplantation,
pubmed-meshheading:12105256-Male,
pubmed-meshheading:12105256-Postoperative Complications,
pubmed-meshheading:12105256-Prednisolone,
pubmed-meshheading:12105256-Recombinant Fusion Proteins,
pubmed-meshheading:12105256-Time Factors,
pubmed-meshheading:12105256-Transplantation, Homologous,
pubmed-meshheading:12105256-Treatment Outcome
|
pubmed:year |
2002
|
pubmed:articleTitle |
Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
|
pubmed:affiliation |
Department of Paediatric Nephrology, Guy's Hospital, London, UK. godfrey.clark@kcl.ac.uk
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Controlled Clinical Trial
|